Europa-Marktprognose für Antikörper-Wirkstoffkonjugate bis 2030 – regionale Analyse – nach Technologie (spaltbarer Linker und nicht spaltbarer Linker), Anwendung (Blutkrebs, Brustkrebs, Eierstockkrebs, Urothelkrebs und andere) und Vertriebskanal (Krankenhausapotheken, Einzelhandel). Apotheken und Online-Apotheken)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 104    |    Report Code: BMIRE00029768    |    Category: Life Sciences

Europe Antibody Drug Conjugates Market
Der europäische Markt für Antikörper-Wirkstoffkonjugate wurde im Jahr 2022 auf 2.263,14 Millionen US-Dollar geschätzt und wird bis 2030 voraussichtlich 7.947,86 Millionen US-Dollar erreichen; Von 2022 bis 2030 wird ein durchschnittliches jährliches Wachstum von 17,0 % erwartet.

Steigende Investitionen in die Entwicklung von ADCs befeuern den europäischen Markt für Antikörper-Wirkstoff-Konjugate

ADCs sind ein Game-Changer im Bereich der Onkologie ; Diese werden weithin zur Behandlung von Brustkrebs eingesetzt. Mehrere Unternehmen investieren enorm in die Entwicklung neuartiger ADCs. Im Mai 2022 gab Evotec SE eine große strategische Kapitalbeteiligung an der Tubulis GmbH zur Entwicklung von ADCs bekannt. Evotec SE hat 64 Millionen US-Dollar (60 Millionen US-Dollar) in die Finanzierungsrunde der Tubliss-Serie B investiert, die von Andera Partners geleitet wird. Ebenso gab Spirea Limited im Juni 2022 bekannt, dass es Investitionen in Höhe von 3 Millionen US-Dollar erhalten hat (

Europe Antibody Drug Conjugates Strategic Insights

Strategic insights for Europe Antibody Drug Conjugates involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-antibody-drug-conjugates-market-strategic-framework.webp
Get more information on this report

Europe Antibody Drug Conjugates Report Scope

Report Attribute Details
Market size in 2022 US$ 2,263.14 Million
Market Size by 2030 US$ 7,947.86 Million
Global CAGR (2022 - 2030) 17.0%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By Technologie
  • Spaltbarer Linker
  • Nicht-Spaltbarer Linker
By Anwendung
  • Blutkrebs
  • Brustkrebs
  • Eierstockkrebs
  • Urothelkrebs
By Vertriebskanäle
  • Krankenhausapotheken
  • Einzelhandelsapotheken
  • Online-Apotheken
Regions and Countries Covered Europa
  • Großbritannien
  • Deutschland
  • Frankreich
  • Russland
  • Italien
  • Rest von Europa
Market leaders and key company profiles
  • ADC Therapeutics SA
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • ImmunoGen, Inc
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • Takeda Pharmaceutical Co Ltd
  • Get more information on this report

    Europe Antibody Drug Conjugates Regional Insights

    The regional scope of Europe Antibody Drug Conjugates refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-antibody-drug-conjugates-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Antibody Drug Conjugates Market

    1. ADC Therapeutics SA
    2. Pfizer Inc
    3. Hoffmann-La Roche Ltd
    4. ImmunoGen, Inc
    5. GSK Plc
    6. Gilead Sciences Inc
    7. AstraZeneca Plc
    8. Astellas Pharma Inc
    9. Takeda Pharmaceutical Co Ltd

    Frequently Asked Questions
    How big is the Europe Antibody Drug Conjugates Market?

    The Europe Antibody Drug Conjugates Market is valued at US$ 2,263.14 Million in 2022, it is projected to reach US$ 7,947.86 Million by 2030.

    What is the CAGR for Europe Antibody Drug Conjugates Market by (2022 - 2030)?

    As per our report Europe Antibody Drug Conjugates Market, the market size is valued at US$ 2,263.14 Million in 2022, projecting it to reach US$ 7,947.86 Million by 2030. This translates to a CAGR of approximately 17.0% during the forecast period.

    What segments are covered in this report?

    The Europe Antibody Drug Conjugates Market report typically cover these key segments-

  • Technologie (Spaltbarer Linker, Nicht-Spaltbarer Linker)
  • Anwendung (Blutkrebs, Brustkrebs, Eierstockkrebs, Urothelkrebs)
  • Vertriebskanäle (Krankenhausapotheken, Einzelhandelsapotheken, Online-Apotheken)
  • What is the historic period, base year, and forecast period taken for Europe Antibody Drug Conjugates Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Antibody Drug Conjugates Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Europe Antibody Drug Conjugates Market?

    The Europe Antibody Drug Conjugates Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • ADC Therapeutics SA
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • ImmunoGen, Inc
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • Takeda Pharmaceutical Co Ltd
  • Who should buy this report?

    The Europe Antibody Drug Conjugates Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Antibody Drug Conjugates Market value chain can benefit from the information contained in a comprehensive market report.